statistiche ricercatore

Continente	#
AS - Asia	782
NA - Nord America	404
EU - Europa	202
SA - Sud America	36
Continente sconosciuto - Info sul continente non disponibili	35
AF - Africa	28
OC - Oceania	1
Totale	1.488

Nazione	#
US - Stati Uniti d'America	388
VN - Vietnam	222
CN - Cina	211
SG - Singapore	180
IT - Italia	100
HK - Hong Kong	41
KR - Corea	34
BR - Brasile	23
IN - India	23
BD - Bangladesh	19
DE - Germania	19
NL - Olanda	15
FI - Finlandia	13
FR - Francia	12
GB - Regno Unito	12
JP - Giappone	12
CA - Canada	8
CI - Costa d'Avorio	8
ID - Indonesia	8
PH - Filippine	7
MX - Messico	6
NG - Nigeria	6
RU - Federazione Russa	6
TH - Thailandia	6
IE - Irlanda	5
ZA - Sudafrica	5
AT - Austria	4
CL - Cile	4
JO - Giordania	4
LT - Lituania	4
SC - Seychelles	4
TW - Taiwan	4
AR - Argentina	3
CO - Colombia	3
SE - Svezia	3
BG - Bulgaria	2
ES - Italia	2
IQ - Iraq	2
PK - Pakistan	2
SA - Arabia Saudita	2
TG - Togo	2
AL - Albania	1
AU - Australia	1
BE - Belgio	1
CH - Svizzera	1
CR - Costa Rica	1
DZ - Algeria	1
EC - Ecuador	1
EG - Egitto	1
IS - Islanda	1
JM - Giamaica	1
MA - Marocco	1
MY - Malesia	1
NP - Nepal	1
OM - Oman	1
PY - Paraguay	1
SK - Slovacchia (Repubblica Slovacca)	1
TR - Turchia	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.453

Nome	#
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies	216
Classic versus innovative strategies for immuno-therapy in pancreatic cancer	163
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue	140
Advanced non-small-cell lung cancer: how to manage non-oncogene disease	135
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients	132
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma	124
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis	117
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma	95
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review	91
Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients	82
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)	80
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?	72
Molecular hydrogen therapy: A “democratic” emerging strategy against aging and age-related diseases	41
Totale	1.488

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	12	0	0	0	0	0	0	0	3	1	0	6	2
2022/2023	19	1	3	0	1	1	1	1	2	7	0	2	0
2023/2024	53	2	2	1	1	7	8	3	10	8	5	4	2
2024/2025	332	18	27	25	20	34	14	23	10	15	33	38	75
2025/2026	1.042	68	97	89	100	76	30	139	35	194	71	68	75
2026/2027	30	30	0	0	0	0	0	0	0	0	0	0	0
Totale													1.488

CRIS Current Research Information System